Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 20s Proteasome Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| 20s Proteasome Products under Development by Stage of Development | 7 | 1 |
| 20s Proteasome Products under Development by Therapy Area | 8 | 1 |
| 20s Proteasome Products under Development by Indication | 9 | 2 |
| 20s Proteasome Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| 20s Proteasome Products under Development by Companies | 13 | 3 |
| 20s Proteasome Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| 20s Proteasome Companies Involved in Therapeutics Development | 21 | 3 |
| Amgen Inc. | 21 | 2 |
| LG Life Science LTD. | 23 | 1 |
| 20s Proteasome Drug Profiles | 24 | 23 |
| carfilzomib Drug Profile | 24 | 11 |
| marizomib Drug Profile | 35 | 4 |
| oprozomib Drug Profile | 39 | 3 |
| Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor Drug Profile | 42 | 1 |
| VPE-001 Drug Profile | 43 | 1 |
| VPEA-002 Drug Profile | 44 | 1 |
| VPEA-004 Drug Profile | 45 | 1 |
| VR-23 Drug Profile | 46 | 1 |
| 20s Proteasome Dormant Projects | 47 | 1 |
| 20s Proteasome Featured News &Press Releases | 48 | 21 |
| Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression | 48 | 4 |
| Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 | 52 | 1 |
| Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen | 53 | 1 |
| Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma | 54 | 1 |
| Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers | 55 | 1 |
| May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma | 55 | 1 |
| May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" | 56 | 1 |
| May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association | 57 | 2 |
| May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 | 59 | 1 |
| Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma | 60 | 1 |
| Feb 12, 2016: New Drug Treatment Kyprolis (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK | 60 | 2 |
| Jan 21, 2016: FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma | 62 | 2 |
| Dec 08, 2015: Triphase Accelerator to Present Marizomib Clinical and Preclinical Data at Annual Meeting of the American Society of Hematology | 64 | 1 |
| Dec 05, 2015: Amgen Submits Application In Europe To Expand Indication Of Kyprolis (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma | 65 | 1 |
| Dec 05, 2015: New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis (Carfilzomib) As Backbone Therapy In Multiple Myeloma | 66 | 3 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |